Peter W. Hinchliffe

Calon Cardio-Technology Ltd. develops implantable micro blood pumps for the treatment of chronic heart failure. Its lead product, the MiniVAD, a miniature implantable blood pump, is being developed for implantation directly into the left ventricle of the failing heart to help provide adequate blood supply to the body, alleviate the debilitating symptoms of heart failure and improve quality of life. The company was founded by Marc Clement in 2007 and is headquartered in Swansea, the United Kingdom.

Calon Cardio-Technology Ltd. develops implantable micro blood pumps for the treatment of chronic heart failure. Its lead product, the MiniVAD, a miniature implantable blood pump, is being developed for implantation directly into the left ventricle of the failing heart to help provide adequate blood supply to the body, alleviate the debilitating symptoms of heart failure and improve quality of life. The company was founded by Marc Clement in 2007 and is headquartered in Swansea, the United Kingdom.

Calon Cardio-Technology Ltd. develops implantable micro blood pumps for the treatment of chronic heart failure. Its lead product, the MiniVAD, a miniature implantable blood pump, is being developed for implantation directly into the left ventricle of the failing heart to help provide adequate blood supply to the body, alleviate the debilitating symptoms of heart failure and improve quality of life. The company was founded by Marc Clement in 2007 and is headquartered in Swansea, the United Kingdom.

Calon Cardio-Technology Ltd. develops implantable micro blood pumps for the treatment of chronic heart failure. Its lead product, the MiniVAD, a miniature implantable blood pump, is being developed for implantation directly into the left ventricle of the failing heart to help provide adequate blood supply to the body, alleviate the debilitating symptoms of heart failure and improve quality of life. The company was founded by Marc Clement in 2007 and is headquartered in Swansea, the United Kingdom.